[Elsevier] The right dose, not the highest dose: rethinking obesity pharmacotherapy

soleolmos Post time Half hour(s) ago | Show all posts |Read mode
This post will be closed automatically in 2026-11-25 04:36
Reward10points

Edited by soleolmos at 2026-11-22 04:39

Obesity pharmacotherapy has changed drastically in the past decade, moving from a scenario of limited use (partly because of the moderate efficacy of available medications and obesity-related stigma) to one in which glucagon-like peptide-1 (GLP-1) receptor agonists and newer drugs targeting multiple hormonal pathways help people achieve substantial weight loss, with meaningful benefits for obesity-related complications and quality of life, alongside reassuring safety profiles.

Reply

Use magic Donate Report

All Reply0 Show all posts

Reply

You have to log in before you can reply Login | Register

Points Rules

Junior Member
  • post

  • reply

  • points

    190


Return to the list